Castleman Disease
📧 Sign up to get email alerts when something new happens for Castleman Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease [Phase 1]
Phase 1 trial evaluating bevacizumab and temsirolimus alone or with valproic acid or cetuximab in patients with advanced or metastatic malig…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease [Phase 2]
Phase 2 clinical trial evaluating ruxolitinib in previously treated idiopathic multicentric Castleman disease; recruitment ongoing.
-
EMA approval · 2026-03-24EMA Authorised: Sylvant (siltuximab) — Recordati Netherlands B.V.
The European Medicines Agency has authorized Sylvant (siltuximab) for giant lymph node hyperplasia (Castleman disease) with accelerated asse…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: International Registry for Patients With Castleman Disease
ClinicalTrials.gov study NCT02817997 describes an international registry for patients with Castleman disease, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease [NA]
A clinical trial update indicates a study examining the molecular basis of Castleman disease, Langerhans cell histiocytosis, and non-Langerh…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
This ClinicalTrials.gov study from the National Cancer Institute aims to molecularly characterize tumors that are associated with viral infe…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Registry for Adults With Plasma Cell Disorders (PCD's)
Clinical trial registry update for adults with plasma cell disorders indicating active recruitment. The study is sponsored by UNC Lineberger…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease [Phase 2]
A Phase 2 trial of sirolimus for previously treated idiopathic multicentric Castleman disease has posted results, and the study is currently…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: AutoInflammatory Disease Alliance Registry (AIDA)
The AutoInflammatory Disease Alliance Registry (AIDA) is currently recruiting to collect data on hereditary autoinflammatory diseases. The c…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context
An Italian multicenter retrospective observational study is assessing the effectiveness and safety of siltuximab for Castleman's disease in …
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Nintedanib Treatment in Unicentric Castleman Disease [Phase 2]
Phase 2 clinical trial evaluating nintedanib for unicentric Castleman disease. The study is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2024-05-07Clinical Trial Update: HHV8 and Solid Organ Transplantation
A clinical trial update shows a recruiting study sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, focusing on HHV-8 …
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: Tocilizumab for KSHV-Associated Multicentric Castleman Disease [Phase 2]
Phase 2 trial of tocilizumab for KSHV-associated multicentric Castleman disease has completed with results posted.
-
CLINICAL_TRIALS withdrawal · 2018-07-31Clinical Trial Update: Castleman Disease Collaborative Network Biobank
The Castleman Disease Collaborative Network Biobank clinical trial (NCT02871050) has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-18Clinical Trial Update: Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease [Phase 4]
A Phase 4 clinical trial evaluating valganciclovir for HHV-8-associated multicentric Castleman disease was withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-11-02Clinical Trial Update: A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment [Phase 1]
Phase 1 trial assessing continuation of RoActemra/Actemra (tocilizumab) in patients with multicentric Castleman's disease who previously ben…
-
CLINICAL_TRIALS trial_result · 2016-06-10Clinical Trial Update: Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors [EARLY_Phase 1]
Early-phase 1 clinical trial update for nelfinavir in gammaherpesvirus-related tumors, noting termination of the study despite investigation…
-
CLINICAL_TRIALS trial_result · 2014-07-01Clinical Trial Update: A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease [Phase 1]
This document reports the completion of a Phase 1 safety and efficacy study of CNTO-328 (siltuximab) in patients with B-cell non-Hodgkin lym…
-
EMA approval · 2014-03-21European Medicines Agency recommends authorisation of first medicine for Castleman's disease
The EMA recommends authorisation of the first medicine specifically for Castleman’s disease, marking a pivotal step in treatment options for…
-
CLINICAL_TRIALS trial_result · 2013-02-04Clinical Trial Update: Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease [Phase 2]
Phase 2 trial evaluating suramin for refractory or relapsed multiple myeloma or Castleman's disease has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-15Clinical Trial Update: Dose-escalation Study of Oral CX-4945 [Phase 1]
Phase 1 dose-escalation study of CX-4945 in patients with various cancers is underway, including breast cancer, inflammatory breast cancer, …